Feijen EAM, et al. - Researchers assessed optimal dose equivalence ratios for late-onset cardiomyopathy between doxorubicin and other anthracyclines or the anthraquinone mitoxantrone among childhood cancer survivors. In this multicenter cohort study of 28,423 childhood cancer survivors with comprehensive cancer treatment exposures, it was noted that the anthraquinone mitoxantrone vs doxorubicin was correlated with more cardiotoxic risk than current guidelines would suggest; the anthracycline daunorubicin was linked with less cardiotoxic risk. Findings suggested anthracycline epirubicin as isoequivalent to doxorubicin. Daunorubicin was linked with lower risk of cardiomyopathy vs doxorubicin, while the existing hematologic-based doxorubicin dose equivalency of mitoxantrone (4:1) seemed to significantly underestimate the correlation of mitoxantrone with long-term cardiomyopathy risk.